anti-mutant calreticulin monoclonal antibody inca033989
anti-mutant calreticulin monoclonal antibody inca033989: 4 clinical trials tracked.
anti-mutant calreticulin monoclonal antibody inca033989 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about anti-mutant calreticulin monoclonal antibody inca033989, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (4)
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
Primary endpoint: Durable clinicohematologic response (DCR)
A Phase 1, Single Dose, Open-Label, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
Primary endpoint: Pharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusion
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)